Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.52)
# 901
Out of 4,987 analysts
223
Total ratings
48.12%
Success rate
5.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $38.95 | +102.82% | 5 | Sep 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $19 → $18 | $6.77 | +165.88% | 4 | Sep 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $158 → $163 | $145.15 | +12.30% | 29 | Sep 5, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $162 → $163 | $130.82 | +24.60% | 9 | Aug 28, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $61.99 | +14.53% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $6.11 | +358.27% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $12.50 | +68.00% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $1.86 | +7.53% | 4 | Aug 18, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $17 → $13 | $7.09 | +83.36% | 6 | Aug 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $100 → $109 | $98.12 | +11.09% | 12 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $8.34 | +1,194.96% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $28.78 | +91.10% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $24.60 | -2.44% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $60.82 | +39.76% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $22.59 | +19.52% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $5.24 | -4.58% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $48.58 | +37.92% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.09 | +332.85% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $35.50 | +97.18% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.03 | +288.35% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.24 | +222.58% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $8.72 | +60.55% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.28 | +52.44% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.72 | +10.29% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.72 | +713.62% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.19 | +356.62% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $40.42 | -45.57% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $15.44 | +861.79% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.49 | +3,926.85% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.49 | +33.78% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $5.52 | +11,639.13% | 6 | May 8, 2020 |
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $38.95
Upside: +102.82%
enGene Holdings
Sep 12, 2025
Maintains: Overweight
Price Target: $19 → $18
Current: $6.77
Upside: +165.88%
Neurocrine Biosciences
Sep 5, 2025
Maintains: Overweight
Price Target: $158 → $163
Current: $145.15
Upside: +12.30%
Jazz Pharmaceuticals
Aug 28, 2025
Maintains: Overweight
Price Target: $162 → $163
Current: $130.82
Upside: +24.60%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $61.99
Upside: +14.53%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $6.11
Upside: +358.27%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $12.50
Upside: +68.00%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $1.86
Upside: +7.53%
Bicycle Therapeutics
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.09
Upside: +83.36%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $100 → $109
Current: $98.12
Upside: +11.09%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $8.34
Upside: +1,194.96%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $28.78
Upside: +91.10%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $24.60
Upside: -2.44%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $60.82
Upside: +39.76%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $22.59
Upside: +19.52%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $5.24
Upside: -4.58%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $48.58
Upside: +37.92%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.09
Upside: +332.85%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $35.50
Upside: +97.18%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.03
Upside: +288.35%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.24
Upside: +222.58%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $8.72
Upside: +60.55%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.28
Upside: +52.44%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.72
Upside: +10.29%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.72
Upside: +713.62%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.19
Upside: +356.62%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $40.42
Upside: -45.57%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $15.44
Upside: +861.79%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.49
Upside: +3,926.85%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.49
Upside: +33.78%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $5.52
Upside: +11,639.13%